Can a comprehensive gadoxetic acid-enhanced MRI with MRCP be used for early diagnosis, monitoring, and outcome prediction of PSC?

Guarantor

The scientific guarantor of this publication is Dr. Ahmed Ba-Ssalamah.

Conflict of interest

The authors of this manuscript declare relationships with the following companies: Sarah Poetter-Lang: nothing to disclose. Ahmed Ba-Ssalamah: honoraria for consulting from Bayer, speaker fees from Bayer and Siemens and Sanofi. This has no relation to this publication. Nina Bastati: nothing to disclose. Emina Halilbasic: nothing to disclose. Michael Trauner: received grant support from Albireo, Cymabay, Falk, Gilead, Intercept, MSD, and Takeda; honoraria for consulting from BiomX, Boehringer Ingelheim, Falk, Genfit, Gilead, Intercept, Janssen, MSD, Novartis, Phenex, and Regulus; speaker fees from BMS, Falk, Gilead, Intercept and MSD, as well as travel support from Abbvie, Falk, Gilead and Intercept.

Statistics and biometry

NA.

Informed consent

Retrospective analysis, Informed Consent waived by IRB.

Ethical approval

Institutional Review Board approval was obtained. Ethics Commission (EC), Nr: 2249/2016 Radiologic Diagnosis of Cholestatic Liver Disease; A Retrospective Data Analysis.

Study subjects or cohort overlap

NA.

Methodology

留言 (0)

沒有登入
gif